SECOND AMENDED AND RESTATED FINANCIAL AND INVESTOR RELATIONS AGREEMENT This Agreement is dated effective as of January 28, 2011.Financial and Investor Relations Agreement • November 1st, 2011 • Helix BioPharma Corp • Pharmaceutical preparations • Ontario
WHEREAS Helix previously retained ACM to provide Helix with investor and financial advisory services in Europe, by execution of the Financial and Investor Relations Agreement dated as of January 25, 2010 (hereinafter referred to as the “Original Agreement”);
HELIX BIOPHARMA CORP. HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT OF SELECTED PORTIONS OF THIS...Manufacturing Agreement • November 1st, 2011 • Helix BioPharma Corp • Pharmaceutical preparations
This third amendment agreement (“Third Amendment”) is made this 1 day of October, 2010 by and between Helix Biopharma Corporation (“Helix”), a corporation organized and existing under the laws of Canada and having its principal offices located at 305 Industrial Parkway South, Unit 3, Aurora, Ontario, L4G 6X7, Contract Pharmaceuticals Limited Niagara (“CPL”), a corporation organized and existing under the laws of Delaware and having a place of business located at 100 Forest Avenue, Buffalo, New York, 14213, and Contract Pharmaceuticals Limited Canada (“CPL Canada”), a corporation organized and existing under the laws of Ontario, Canada and having its principal offices at 7600 Danbro Crescent, Mississauga, Ontario, Canada, L5N 6L6.
Helix BioPharma Corp. STOCK OPTION AGREEMENT (2010 Equity Compensation Plan – Directors and Officers)Stock Option Agreement • November 1st, 2011 • Helix BioPharma Corp • Pharmaceutical preparations
TECHNOLOGY LICENCE AGREEMENT AMENDMENTTechnology License Agreement • November 1st, 2011 • Helix BioPharma Corp • Pharmaceutical preparations
